Saturday | 30 August, 2008
Avexa partners for hep C
Avexa to collaborate with TargetDrug on HCV program
Additional Resources
Newsletter Subscription
Avexa (ASX: AVX) has announced plans to collaborate with Chinese pharmaceutical company TargetDrug on its hepatitis C virus (HCV) program.
Avexa is a Melbourne-based biotechnology company which is searching for new treatments for HCV. In this second stage of its research, the company will attempt to develop new methods to inhibit HCV replication.
Datamonitor estimates the already lucrative HCV market will grow to $4.4 billion by 2010.
Avexa also announced that the first of its Phase III studies of apricitabine for drug-resistant HIV is progressing well, with the first component of recruitment due to be completed in the third quarter of this year.
More about Datamonitor, Billion
Australian Life Scientist Member Login
Beyond The Hybrid TV Card Norm 2008-08-26 15:29:00+10
Go Green with Kingston - Save the PCB, Save the World 2008-08-25 16:10:00+10
VIA Pico-ITX at the Heart of Modern Robots 2008-08-25 13:50:00+10
Fujitsu unveils winning formula for success with Intel® Centrino® 2 processor technology. 2008-08-25 12:42:00+10
Multimedia Technology & Herma Technologies announce new audience feedback solution from REPLY Systems. 2008-08-19 11:05:00+10
Sponsored Links
Subscribe to Australian Life Scientist
Australian Life Scientist is Australia's leading magazine for the life sciences sector. ALS is available free of charge to qualified persons working in the life sciences - register now for your free subscription.
